Ovarian tumor expression is dependent on the functions of the somatic sex regulatory genes transformer-2 and doublesex.

Arthropod Struct Dev

Department of Biological Sciences, University of Iowa, Iowa City, IA 52242-1234, USA.

Published: September 2002

The doublesex-dependent sex regulatory pathway in Drosophila controls major aspects of somatic sexual differentiation, but its expression is not required in the X/X germline. Nevertheless, mutations in doublesex and in the genes that directly regulate its expression, transformer and transformer-2, disrupt early stages of oogenic differentiation to produce gonads containing immature germ cells. This indicates a critical, but uncharacterized, set of soma-germline interactions essential for oogenesis. In this paper, we examined the effects of mutations in transformer-2 on the expression and function of the germline-specific ovarian tumor gene. We demonstrated that in transformer-2 mutants, there was a marked reduction in the activity of the ovarian tumor promoter in the mutant germline. In addition, the phenotypic effects on the arrested germline could be partially suppressed by the simultaneous over-expression of both ovarian tumor and a second germline gene, Sex-lethal. This differs from transformer mutations, in which the over-expression of ovarian tumor alone is sufficient for a similar improvement in germline differentiation. In contrast to transformer-2, doublesex activity was not required for ovarian tumor promoter activity and we found indirect evidence that the doublesex male-specific function might have a negative regulatory effect. These data indicate that the components of the genetic pathway regulating somatic sexual differentiation have specific and differential effects on germline gene activity.

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1467-8039(02)00020-8DOI Listing

Publication Analysis

Top Keywords

ovarian tumor
24
sex regulatory
8
transformer-2 doublesex
8
somatic sexual
8
sexual differentiation
8
tumor promoter
8
over-expression ovarian
8
germline gene
8
ovarian
6
germline
6

Similar Publications

Background: Ovarian cancer (OC), particularly high-grade serous ovarian carcinoma (HGSOC), is the leading cause of mortality from gynecological malignancies worldwide. Despite the initial effectiveness of treatment, acquired resistance to poly(ADP-ribose) polymerase inhibitors (PARPis) represents a major challenge for the clinical management of HGSOC, highlighting the necessity for the development of novel therapeutic strategies. This study investigated the role of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), a pivotal regulator of glycolysis, in PARPi resistance and explored its potential as a therapeutic target to overcome PARPi resistance.

View Article and Find Full Text PDF

Background: Ovarian cancers (OC) and cervical cancers (CC) have poor survival rates. Tumor-infiltrating lymphocytes (TILs) play a pivotal role in prognosis, but shared immune mechanisms remain elusive.

Methods: We integrated single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) to explore immune regulation in OC and CC, focusing on the PI3K/AKT pathway and FLT3 as key modulators.

View Article and Find Full Text PDF

A safe haven for cancer cells: tumor plus stroma control by DYRK1B.

Oncogene

January 2025

Department of Gastroenterology, Endocrinology and Metabolism, Center for Tumor and Immune Biology, Philipps University Marburg, Marburg, Germany.

The development of resistance remains one of the biggest challenges in clinical cancer patient care and it comprises all treatment modalities from chemotherapy to targeted or immune therapy. In solid malignancies, drug resistance is the result of adaptive processes occurring in cancer cells or the surrounding tumor microenvironment (TME). Future therapy attempts will therefore benefit from targeting both, tumor and stroma compartments and drug targets which affect both sides will be highly appreciated.

View Article and Find Full Text PDF

The aim of the study is to analyze the relationship between personality traits of women with hereditary predisposition to breast/ovarian cancer and their obstetric history and cancer-preventive behaviors. A total of 357 women, participants of 'The National Program for Families With Genetic/Familial High Risk for Cancer', were included in the study. The Neo Five-Factor Inventory (NEO-FFI) and a standardized original questionnaire designed for the purpose of the study were used.

View Article and Find Full Text PDF

MUC1 and glycan probing of CA19-9 captured biomarkers from cyst fluids and serum provides enhanced recognition of ovarian cancer.

Sci Rep

January 2025

Department of Life Technologies, Division of Biotechnology, University of Turku, Medisiina D, 5th floor, Kiinamyllynkatu 10, 20520, Turku, Finland.

Glycosylation changes of circulating proteins carrying the CA19-9 antigen may offer new targets for detection methods to be explored for the diagnosis of epithelial ovarian cancer (EOC). Search for assay designs for targets initially captured by a CA19-9 antigen reactive antibody from human body fluids by probing with fluorescent nanoparticles coated with lectins or antibodies to known EOC associated proteins. CA19-9 antigens were immobilized from ascites fluids, ovarian cyst fluids or serum samples using monoclonal antibody C192 followed by probing of carrier proteins using anti-MUC16, anti-MUC1 and, anti STn antibodies and seven lectins, all separately coated on nanoparticles.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!